NASDAQ$RNA

Atrium Therapeutics Inc · Q3 2024 earnings

Q3 2024 earnings ·

Briefing

RNA Q3 2024 — $2.3M revenue, 0.65 EPS

Any of these actions could materially harm the Company’s business, results of operations and future prospects. Atrium Therapeutics Inc reported Q3 2024 results. Diluted EPS came in at $0.65. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $2.3M.
  • Diluted EPS: $0.65.
  • Filed on Form 10-Q (accession 0001599901-24-000186).

Headline financials

Total Revenue

$2.34M

Previous: $2.82M-17.1%
EPS

-$0.65

Previous: -$0.71+8.5%
Capital Expenditures

-$3.15M

Previous: -$3.37M+6.4%
Free Cash Flow

-$83.5M

Previous: -$55.7M-49.9%
Net Income

-$80.4M

Previous: -$52.4M-53.6%
Operating Income

-$98.1M

Previous: -$58.6M-67.4%

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$2.34M

Q3 2024-17.1%vs Q3 2023
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro